1. Home
  2. CRBP vs CGO Comparison

CRBP vs CGO Comparison

Compare CRBP & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • CGO
  • Stock Information
  • Founded
  • CRBP 2009
  • CGO 2004
  • Country
  • CRBP United States
  • CGO United States
  • Employees
  • CRBP N/A
  • CGO N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • CGO Investment Managers
  • Sector
  • CRBP Health Care
  • CGO Finance
  • Exchange
  • CRBP Nasdaq
  • CGO Nasdaq
  • Market Cap
  • CRBP 110.3M
  • CGO 114.2M
  • IPO Year
  • CRBP N/A
  • CGO N/A
  • Fundamental
  • Price
  • CRBP $8.90
  • CGO $11.55
  • Analyst Decision
  • CRBP Strong Buy
  • CGO
  • Analyst Count
  • CRBP 10
  • CGO 0
  • Target Price
  • CRBP $53.56
  • CGO N/A
  • AVG Volume (30 Days)
  • CRBP 124.3K
  • CGO 34.7K
  • Earning Date
  • CRBP 08-05-2025
  • CGO 01-01-0001
  • Dividend Yield
  • CRBP N/A
  • CGO 9.25%
  • EPS Growth
  • CRBP N/A
  • CGO N/A
  • EPS
  • CRBP N/A
  • CGO N/A
  • Revenue
  • CRBP N/A
  • CGO N/A
  • Revenue This Year
  • CRBP N/A
  • CGO N/A
  • Revenue Next Year
  • CRBP $270.04
  • CGO N/A
  • P/E Ratio
  • CRBP N/A
  • CGO N/A
  • Revenue Growth
  • CRBP N/A
  • CGO N/A
  • 52 Week Low
  • CRBP $4.64
  • CGO $7.90
  • 52 Week High
  • CRBP $61.89
  • CGO $10.93
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 53.56
  • CGO 47.77
  • Support Level
  • CRBP $9.10
  • CGO $11.30
  • Resistance Level
  • CRBP $9.80
  • CGO $11.77
  • Average True Range (ATR)
  • CRBP 0.62
  • CGO 0.14
  • MACD
  • CRBP 0.01
  • CGO -0.03
  • Stochastic Oscillator
  • CRBP 31.45
  • CGO 53.19

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About CGO Calamos Global Total Return Fund

Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.

Share on Social Networks: